INO INOVIO PHARMACEUTICALS INC

Ownership history in CITADEL ADVISORS LLC  ·  19 quarters on record

AI Ownership Summary

CITADEL ADVISORS LLC reported INOVIO PHARMACEUTICALS INC (INO) in 19 quarterly 13F filings from 2024 Q1 through 2025 Q4. The latest visible filing shows INO at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this INO ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was CITADEL ADVISORS LLC's position in INOVIO PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

INO was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2024 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How CITADEL ADVISORS LLC held INO — position size vs. price
% of Fund (quarterly)    INO price (quarter-end, indexed to 100)
📋 Quarterly Holdings History 19 quarters  
Quarter Action Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 ADDED 384,200 +339,300 +755.7% 0.00% $669K 2026-02-14 (Est.) $1.61
2025 Q4 ADDED 44,900 +33,800 +304.5% 0.00% $78K 2026-02-14 (Est.) $1.61
2025 Q3 REDUCED 11,100 -1,302 -10.5% 0.00% $26K 2025-11-14 $2.05
2025 Q3 REDUCED 12,402 -108,098 -89.7% 0.00% $29K 2025-11-14 $2.05
2025 Q3 ADDED 120,500 +55,100 +84.3% 0.00% $282K 2025-11-14 $2.05
2025 Q2 ADDED 65,400 +41,300 +171.4% 0.00% $133K 2025-08-14 $1.62
2025 Q2 REDUCED 24,100 -144,856 -85.7% 0.00% $49K 2025-08-14 $1.62
2025 Q2 ADDED 168,956 +161,256 +2094.2% 0.00% $344K 2025-08-14 $1.62
2025 Q1 REDUCED 7,700 -13,700 -64.0% 0.00% $13K 2025-05-15 $1.95
2025 Q1 REDUCED 21,400 -5,760 -21.2% 0.00% $35K 2025-05-15 $1.95
2024 Q4 ADDED 27,160 +5,432 +25.0% 0.00% $50K 2025-02-14 $2.15
2024 Q4 REDUCED 21,728 -1,112 -4.9% 0.00% $40K 2025-02-14 $2.15
2024 Q4 ADDED 22,840 +8,760 +62.2% 0.00% $42K 2025-02-14 $2.15
2024 Q3 REDUCED 14,080 -28,588 -67.0% 0.00% $81K 2024-11-14 $4.77
2024 Q3 ADDED 42,668 +27,028 +172.8% 0.00% $247K 2024-11-14 $4.77
2024 Q2 REDUCED 15,640 -22,508 -59.0% 0.00% $126K 2024-08-14 $7.82
2024 Q2 ADDED 38,148 +19,124 +100.5% 0.00% $308K 2024-08-14 $7.82
2024 Q1 REDUCED 19,024 -38,296 -66.8% 0.00% $264K 2024-05-15 $13.07
2024 Q1 INITIATED 57,320 0.00% $796K 2024-05-15 $13.07

FAQ About CITADEL ADVISORS LLC and INO

These are the practical questions this page is built to answer before you even open the full history table.

How long has CITADEL ADVISORS LLC reported owning INO?

CITADEL ADVISORS LLC reported INO across 19 quarterly 13F filings, from 2024 Q1 through 2025 Q4.

What was the largest reported INO position in CITADEL ADVISORS LLC's portfolio?

The largest reported portfolio weight for INO was 0.00% in 2024 Q1.

What is the latest reported INO position on this page?

The most recent filing on this page is 2025 Q4, when CITADEL ADVISORS LLC reported 384,200 shares, equal to 0.00% of portfolio, with an estimated market value of $669K.

What does the chart on this INO ownership page compare?

The chart compares CITADEL ADVISORS LLC's quarterly INO portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to CITADEL ADVISORS LLC Holdings